uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
08 août 2022 07h05 HE | uniQure Inc.
~ Announced 12-month data on the lower-dose cohort of AMT-130 in Huntington’s disease showed the investigative gene therapy was generally well tolerated at this dose with a mean reduction of 53.8% of...
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 août 2022 16h01 HE | Freeline Therapeutics Holdings plc
LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole...
Asia Pacific Cancer Gene Therapy Market Report 2022: Featuring Key Players Novartis, GlaxoSmithKline, Amgen, Bristol Myers Squibb, Gilead Sciences,. Adaptimmune, Genelux & Sarepta Therapeutics,
04 août 2022 04h53 HE | Research and Markets
Dublin, Aug. 04, 2022 (GLOBE NEWSWIRE) -- The "Asia Pacific Cancer Gene Therapy Market Size, Share & Industry Trends Analysis Report By Therapy (Gene Induced Immunotherapy, Oncolytic...
ocugen_4C_LOGO (002).png
Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results
29 juil. 2022 07h30 HE | Ocugen
MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel cell and...
AGC Biologics Supports Altheia Science’s Gene Therapy Programs
28 juil. 2022 08h00 HE | AGC Biologics
SEATTLE, MILAN, July 28, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with...
Global Viral Vector & Plasmid DNA Manufacturing Market Report to 2027 - Featuring ABL, Biovian and GE Healthcare Among Others
28 juil. 2022 06h13 HE | Research and Markets
Dublin, July 28, 2022 (GLOBE NEWSWIRE) -- The "Viral Vector & Plasmid DNA Manufacturing Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's...
The gene therapy market is projected to be worth USD 17.3 billion in 2035, growing at a CAGR of 18%, during the period 2022-2035, claims Roots Analysis
27 juil. 2022 10h00 HE | Roots Analysis
London, July 27, 2022 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Gene Therapy Market” report to its list of offerings. Post the emergence of blockbuster gene therapies, such...
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
21 juil. 2022 07h00 HE | Freeline Therapeutics
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the New England Journal of Medicine (NEJM) published positive data that expand upon...
Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities
19 juil. 2022 08h00 HE | Frontera Therapeutics
FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may...
Adverum Biotechnologies Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After a Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD
15 juil. 2022 08h32 HE | Adverum Biotechnologies, Inc.
- Study participants had an 81%-98% reduction in annualized anti-VEGF injections and demonstrated continuous aflibercept expression levels through three years - Mean best-corrected visual acuity...